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1. Introduction
Porcine reproductive and respiratory syndrome virus
(PRRSV) is a global threat to the swine industry and
vaccination provides limited protection. During PRRSV
infection one of the most abundant viral proteins produced
within the cell is the nucleocapsid (N) protein. This protein
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A B S T R A C T
Porcine reproductive and respiratory syndrome virus (PRRSV) is a major threat to the
swine industry and food security worldwide. The nucleocapsid (N) protein is a major
structural protein of PRRSV. The primary function of this protein is to encapsidate the viral
RNA genome, and it is also thought to participate in the modulation of host cell biology and
recruitment of cellular factors to facilitate virus infection. In order to the better understand
these latter roles the cellular interactome of PRRSV N protein was deﬁned using label free
quantitative proteomics. This identiﬁed several cellular factors that could interact with the
N protein including poly [ADP-ribose] polymerase 1 (PARP-1), a cellular protein, which can
add adenosine diphosphate ribose to a protein. Use of the PARP-1 small molecule inhibitor,
3-AB, in PRRSV infected cells demonstrated that PARP-1 was required and acted as an
enhancer factor for virus biology. Serial growth of PRRSV in different concentrations of 3-
AB did not yield viruses that were able to grow with wild type kinetics, suggesting that by
targeting a cellular protein crucial for virus biology, resistant phenotypes did not emerge.
This study provides further evidence that cellular proteins, which are critical for virus
biology, can also be targeted to ablate virus growth and provide a high barrier for the
emergence of drug resistance.
 2014 Elsevier B.V. All rights reserved.
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L. Liu et al. / Veterinary Microbiology 176 (2015) 109–119110has important roles in the virus life cycle and may have
critical interactions with the host cell (Rowland et al.,
1999; Sun et al., 2012). At a basic level N protein complexes
with virus genomic RNA to form the ribonucleocapsid core
and as such is an integral component of the enveloped
virus particle (Song et al., 2011). Because the N protein
forms a close association with genomic RNA and other
virus proteins such as those involved in replication and
components of the viral envelope, the protein has been
postulate to play an important role in virus RNA synthesis
and virion assembly, perhaps in the modulation of these
events (Lee et al., 2006).
The interaction of N protein and the host cell has been
supported by several studies showing the association of
this viral protein with cellular proteins including those
involved in nuclear import such as importin-a and
importin-b, the nucleolar protein ﬁbrillarin (Yoo et al.,
2003), and inhibitor of MyoD (a protein belonging to
myogenic regulatory factors) family-a domain-containing
protein (Song et al., 2009). Interactome analysis of the N
protein using over expression and EGFP-trapping coupled
to LC–MS/MS revealed further potential interactions
including association with proteins involved in translation
initiation and RNA post-transcriptional modiﬁcation,
including poly(A) binding protein (PABP), inducible PABP
(iPABP), translation initiation factor 4E (eIF4E) and
heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)
(Jourdan et al., 2012a). Use of RNA silencing of PABP mRNA
and ablation of the protein in PRRSV infected cells
highlighted a positive role for this protein in infection
and demonstrated that host cell proteins are critical for
virus biology (Wang et al., 2012).
In order to generate a more comprehensive analysis of
cellular proteins that could complex with PRRSV N protein
we used an interactome approach in which N protein was
expressed and puriﬁed exogenously and used as bait.
Whilst over-expression analysis coupled to EGFP traps can
provide a useful way of determining the interactome of a
particular viral (or cellular) protein (Jourdan et al., 2012a;
Wu et al., 2012), over-expression can turn on cellular stress
pathways and this may lead to a potential bias in the
interactome. To identify potential cellular protein inter-
actions with PRRSV N protein, recombinant expressed and
puriﬁed protein was therefore used as bait and bound to
nickel afﬁnity beads and incubated with HEK293T cellular
lysate. Label free proteomics was used to both identify and
quantify proteins that associated with the N protein bait
and the UBC9 control bait. One hundred and eight proteins
were identiﬁed by two or more peptides bound to the N
protein bait which were also four fold or more abundant
than binding with the UBC9 control bait. Eighteen proteins
were found to be common between this analysis and a
previous analysis using EGFP-N expressed in cells as bait
(Jourdan et al., 2012a), including PABPC4 and PABPC1 as
the top hits.
One of the unique proteins identiﬁed in the current
study was Poly [ADP-ribose] polymerase 1 (PARP-1),
which although normally associated with DNA virus (e.g.
(Grady et al., 2012; Ohsaki et al., 2004; Tempera et al.,
2010)) and retrovirus biology (e.g. (Bueno et al., 2013)) has
also been shown to be an enhancer factor for inﬂuenza
virus biology (Bortz et al., 2011). Use of the PARP-1
inhibitor 3-aminobenzamide (3-AB) in PRRSV infected
cells indicated that PARP-1 acted as a positive factor for
virus biology, and sequential passage of the virus in the
presence of 3-AB did not lead to breakthrough virus. This
study also illustrated how determining the cellular
interactome of a viral protein can be used to select small
molecule inhibitors that can be used to target viral activity
without the emergence of resistant breakthrough viruses.
2. Materials and methods
2.1. Expression of bait proteins
Single colonies from the pTriEx-PRRSV-N (in BL21(DE3)-
pLysS), pHisTEV30a-MBP (His-tagged maltose binding
protein, in BL21(DE3)) and pHisTEV30a-Ubc9 (SUMO
conjugating enzyme, in BL21(DE3)) were cultured overnight
at 37 8C until stationary phase, diluted 1:20 in 100 ml and
cultured further until mid-log phase was reached (ca. OD600
0.5). Protein expression was induced by the addition of
0.4 mM isopropyl-b-D-thio-galactoside (IPTG). Uninduced
samples served as negative controls. Bacteria were lysed in
5 ml lysis buffer (50 mM Tris (pH7.6), 300 mM NaCl, 10 mM
imadaizole, 0.5% (v/v) Triton X-100, 1 mg/ml lysozyme,
10 mg/ml RNase A and 5 mg/ml DNaseI), sonicated and
clariﬁed by centrifugation. Proteins were bound to Ni-NTA
beads (Qiagen) for 1 h at 4 8C, washed (50 mM Tris (pH 7.6),
300 mM NaCl, 1% (v/v) Triton X-100, 20 mM imadaizole) and
their purity was checked by SDS–PAGE followed by
Coomassie blue staining and immunoblotting using aHis
antibodies.
2.2. His-tag interaction studies
Approximately 1  107 HEK293T cells per interaction
were washed in ice-cold PBS and resuspended in 1 ml of
lysis buffer (50 mM Tris (pH 7.5), 150 mM NaCl, 1% (v/
v)NP40,) with 1X protease inhibitor cocktail (Roche),incu-
bated on ice for 15 min, and clariﬁed by centrifugation at
16,000  g, 4 8C. Cellular lysates were mixed with 20 ml Ni-
NTA for 30 min in order to pre-clear the sample of any
proteins which would non-speciﬁcally bind to the Ni-NTA
matrix. Normalized Ni-NTA-bound protein (50 ml) was
mixed with the HEK293T protein lysates overnight at 4 8C.
The following day the beads-protein complexes were
washed three times in ice-cold PBS and eluted in 50 ml 4X
LDS sample buffer (Invitrogen) with 10% DTT analyzed by
silver stain and Western blot and then analyzed by mass
spectrophotometry.
2.3. LC–MS/MS
Protein samples generated by the pulldowns were
separated by one-dimensional SDS–PAGE (4–12% bis-Tris
Novex mini-gel, Invitrogen). The resulting separated
proteins were cut from the gel in six slices and subjected
to in-gel digestion with trypsin. Trypsin digested peptides
were separated using an Ultimate U3000 nanoﬂow LC-
system (Dionex Corporation) consisting of a solvent
degasser, micro and nanoﬂow pumps, ﬂow control module,
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L. Liu et al. / Veterinary Microbiology 176 (2015) 109–119 111 detector and a thermostated autosampler. The HPLC
tem was coupled to a LTQ Orbitrap XL (Thermo Fisher
ntiﬁc Inc.) via a nano ES ion source (Proxeon
systems). Quantiﬁcation was performed with Max-
nt version 1.0.7.4 (Cox and Mann, 2008).
 Cells and virus
MARC-145 cells were cultured in Dulbecco’s modiﬁed
le’s medium (HyClone) containing 10% fetal bovine
um, 2 mM glutamine, 100 units/ml of penicillin and
 units/ml of streptomycin, and maintained at 37 8C
h 5% CO2. A highly pathogenic PRRSV strain, TA-12
nBank accession number HQ416720.1), was used for
 virus infection studies. 3-Aminobenzamide (3-AB), a
petitive inhibitor of PARP-1, was obtained from
ma–Aldrich and dissolved in DMSO. 3-AB was obtained
9% pure as determined by TLC.
 Cell viability assay
MARC-145 cells were seeded in 96-well cell culture
tes at approximately 1  105 cells/well and cultured
20 h at 37 8C in 5% CO2. The medium was replaced
h fresh DMEM supplemented with 2% FBS containing
, 10, 20, 40 mM 3-AB, then the cells were incubated for
 indicated number of hours. Cell viability was
lyzed by measuring the succinate dehydrogenase
el with a MTT Cell Proliferation and Cytotoxicity Assay
 (Beyotime, Beijing, PR China) according to the
nufacturer’s instruction. A dose–response curve was
duced to show the effects of the drug on the cell
bility.
 3-AB treatment and virus infection
MARC-145 cells were infected with PRRSV at a MOI of 1.
er 1 h absorption at 37 8C, virus inoculum was removed
washing with PBS and cells were maintained in DMEM
plemented with 2% FBS containing varying concentra-
s of 3-AB or the corresponding amount of dimethyl
foxide (DMSO, control) at 37 8C. Virus supernatant was
vested at intervals of 24 h and frozen at 80 8C until
ation on Marc-145 cells which was done by endpoint
tion in 96 well plates.
 Indirect immunoﬂuorescence assay (IFA)
MARC-145 cells plated in 96-well plates were infected
h PRRSV at a MOI of 1. At indicated time-points after
ction, the infected cells were washed with PBS, ﬁxed for
in with cold acetone/methanol (1/1 v/v) pre-chilled at
0 8C. After blocking with 5% milk, the ﬁxed cells were
ubated with swine anti-PRRSV serum for 1 h at 37 8C.
ound antibody was washed three times with PBS
taining 0.1% Tween-20 (PBST). FlTC-conjugated rabbit
i-pig IgG (Bioss, Beijing, PR China) was added and
ubated for 1 h at 37 8C. After three washes with PBST, the
 observation was carried out with a ﬂuorescence
roscope (Olympus CKX41), and images were acquired
g DP2-BSW software.
2.8. Western blotting assay
MARC-145 cells, plated in 12-well plates, were harvested
after infection with PRRSV and treatment with 3-AB or
DMSO at the indicated time points. Cell lysates were
subjected to 10% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS–PAGE) followed by blotting onto
polyvinylidene ﬂuoride (PVDF) membranes (Millipore,
Massachusetts, USA). The membranes were primarily
probed with rabbit anti-PARP antibody (Beyotime), swine
anti-PRRSV-1 serum (Liu et al., 2010), or mouse anti-b-actin
mAb (CWBIO, Beijing, PR China). After washing three times
with TBS containing 0.1% Tween-20 (TBST), the membranes
were incubated with horseradish peroxidase-conjugated
goat anti-rabbit IgG (CWBIO), goat anti-swine IgG (Earthox,
San Francisco, USA) or goat anti-mouse IgG (CWBIO) at 37 8C
for 2 h, respectively. Detection was performed using
enhanced chemiluminescence (ECL) reagents (CWBIO)
according to the manufacturer’s instructions.
2.9. Quantitative RT-PCR
Total RNA was extracted from PRRSV infected Marc-145
cells at 24 hpi using Trizol Reagent (CWBIO, Beijing, PR
China). Reverse transcription was completed using Prim-
Script 1st Strand cDNA Synthesis Kit (TaKaRa, Dalian, PR
China) according to the manufacturer’s instructions. Quan-
titative real time RT-PCR ampliﬁcation was performed on
CFX96 Real Time PCR System (BIO-RAD, USA) using SYBR
Primix Ex Taq II (TaKaRa). The viral genomic RNA was
detected using primers Nsp1-F (50-CACCTTGCTTCCG-
GAGTTG-30) and Nsp1-R (50-GAGAGACCGTGCACTGAGA-
CATC-30), and viral subgenomic RNAs were detected using
primers N-F (50-CCCGGGTTGAAAAGCCTCGTGT-30) and N-R
(50-GGCTTCTCCGGGTTTTTCTTCCTA-30). The GAPDH mRNA
was ampliﬁed as the internal control represented the
cellular mRNA level, using primers GAPDH-F (50-GCAAA-
GACTGAACCCACTAATTT-30) and GAPDH-R (50-TTGCCTC-
TGTTGTTACTTGGAGAT-30). The reaction conditions were as
follows: 95 8C for 30 s; 40 cycles of 95 8C for 5 s and 60 8C for
30 s. Relative levels of viral subgenomic and genomic RNA
were calculated using the 244T method of relative
quantiﬁcation with GAPDH.
2.10. 3-AB virus sensitivity assay
The 3-AB sensitivity assay was carried out in a similar
method as that used to assess the effect of HSP90 inhibitors
against HRSV (Geller et al., 2013). Marc-145 cells were
infected with PRRSV strain TA-12 as described. Following
infection, the media was replaced with maintenance media
containing 0.625 mM 3-AB, and infection allowed to
continue until CPE was observed. The resulting virus
was then used to infect fresh Marc-145 cells and the 3-AB
concentration was doubled. This procedure was repeated
until the drug concentration reached 20 mM (passage 6),
then the drug concentration was kept constant until 15
passages were completed. The sensitivity of the resulting
virus at passage 15 was then assessed by endpoint dilution
on Marc-145 cells, and compared to the original input virus
before the treatment with 3-AB.
L. Liu et al. / Veterinary Microbiology 176 (2015) 109–1191123. Results
To investigate the cellular interactions of the PRRSV N
protein and to identify potential cellular proteins that
played important function(s) in virus biology a label free
proteomic approach was used. We have used a similar
mass spectrometry approach to identify the cellular
interactome of Zaire Ebola virus VP24 protein (Garcia-
Dorival et al., 2014). This was coupled to interaction
studies using recombinant His-tagged PRRSV N protein as
bait to pull-down cellular interacting partners.
3.1. Pull-down of cellular interacting proteins
N protein was expressed with a C-terminal His-tag
(Jourdan et al., 2012b) in BL21(DE3)pLyS cells (Fig. 1A, left
panel). To purify the N protein bacterial lysate from the
induced culture was incubated with nickel afﬁnity beads.
Western blot analysis using anti-his antibody indicated
that N protein bound to the nickel afﬁnity beads (Fig. 1A,
right panel). The same was also shown for the UBC9
protein used as a binding control (data not shown).
To identify potential cellular protein interactions with
N protein, the nickel afﬁnity bound N or UBC9 control
protein (with similar molecular weight to N protein) were
incubated with cell lystate prepared from HEK293T cells.
This cell line was chosen because of the superior
annotation of the human genome for protein identiﬁcation
and high level of transfection efﬁciency. Furthermore,
numerous small molecule inhibitors have been identiﬁed
for human proteins, which allowed us to test our
hypothesis that proteomics can be a powerful tool for
identifying therapeutic targets. Potential protein–protein
interactions were visualized by silver stain analysis
(Fig. 1B). The data indicated that cellular proteins were
bound to both N and UBC9 and that these proﬁles were
distinct from each other.
3.2. LC–MS/MS and bioinformatic analyses of the protein
interactome
Label free proteomics was used to compare the
proteome isolated from the N interaction studies to the
proteome isolated from the UBC9 pulldown. Peptide
Fig. 1. (A) Expression of recombinant His-tagged PRRSV-N protein in culture before (U) or after induction with IPTG at hourly times points (indicated). The
position of marker proteins are indicated. N protein expression was conﬁrmed by western blot using a-His antibody. The western blot showed His-speciﬁc
antibody binding to monomeric N protein (15 kDa) and dimeric N protein (37 kDa), indicated by a *. (B) Silver stained gel of the 293 T cell lysate
pulldown assay using either the UBC9 protein or PRRSV N protein as bait. Molecular weight markers are shown and indicated to the left.
freq
a ce
the
cat
pep
dat
app
has
rep
non
the
the
inte
val
pot
pro
Fig. 
cont
to ri
L. Liu et al. / Veterinary Microbiology 176 (2015) 109–119 113uency was then used as a measure of the abundance of
llular protein binding to the N protein bait compared to
 UBC9 control protein. Conﬁdence in protein identiﬁ-
ion is routinely achieved with the use of 2 or more
tides. Examination of this ratio for the N interactome
aset (Fig. 2A) indicated that the modal ratio was
roximately Log2-1, and work by ourselves and others
 previously suggested that the Log2-2 cutoff or more
resents a working threshold for assigning speciﬁc from
-speciﬁc interactions that arise due to binding to either
 matrix or the single chain EGFP antibody component of
 GFP-trap (Trinkle-Mulcahy et al., 2008). Cellular
racting proteins exhibiting ratios of a conservative
ue of 4-fold or greater were therefore considered to
entially represent speciﬁc interacting partners of the N
tein. This resulted in the identiﬁcation of 108 proteins
that could potentially interact with N protein either
individually or as part of larger protein complexes
(supplementary data). These proteins were used in
downstream analysis.
Supplementary material related to this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.
vetmic.2014.11.023.
STRING analysis was used to analyze the interactome
data to identify cellular proteins that may act as larger
functional complexes. These clustered into two main
groups, one set involved in ribosome assembly and
structure and the other set involved in nucleic acid binding
and processing (Fig. 2B).
One hypothesis that could explain the dataset was that
the degree of binding enrichment to N protein merely
reﬂected the abundance of the speciﬁc protein in the total
2. (A) Frequency of cellular proteins that interact with the PRRSV N protein as determined by ratio between the N protein target bait and UBC9 proteinrol bait. (B) Interactome map using the STRING algorithm of cellular proteins that bind to N protein, showing two major clusters, one of which clusters
bosomal proteins (left).
L. Liu et al. / Veterinary Microbiology 176 (2015) 109–119114cellular proteome: i.e. the most abundant cellular proteins
would be over-represented as binding with N protein. To
investigate this we compared the N protein dataset with
the PaxDb:Protein Abundance Across Organisms database
(version 3.0) that ranks proteins according to their
abundance in various human cell types based on spectral
counting data. The eight most abundant proteins at the
time of analysis were recorded as APOA2, RBP4, APOC2,
TTR, ALB, APOA2, ORM1 and TMSB4X. However, none of
these were part of the 108 cellular proteins associated with
the N protein. There was no correlation between binding
efﬁciency and protein abundance in the cell. For example,
PABPC1 with the highest binding ratio of 85 is ranked 1079
out of 20480 proteins, whereas PARP-1 with a binding ratio
of 13 is ranked 556 out of 20480 proteins. In contrast,
TRIM26 is ranked 12950 out of 20480 and has a binding
ratio of 18. Therefore, there was no apparent correlation
between the abundance of a protein in a cell and its
association with N protein.
3.3. Validation of N-interacting protein results by
immunoblot analysis
In our experience there is good agreement between
using quantitative proteomics to identify interacting
partners from pull down-based experiments and subse-
quent follow on experiments using speciﬁc analysis
techniques (Emmott et al., 2013; Jourdan et al., 2012a;
Wu et al., 2012). Nevertheless, aspects of the N protein
interactome were validated by conducting repeat inde-
pendent interaction studies of control and experimental
systems and probing for speciﬁc virus and cellular proteins
by western blot. We used two proteins with a lower and
higher potential binding ratio; hnRNPA2/B1 (ratio 4) and
eIF4 (ratio 45). Both of these proteins interacted with N
protein but not UBC9 indicating the potential speciﬁcity of
the interactions recorded by the LC–MS/MS analysis
(Fig. 3A).
One of the unique proteins identiﬁed in the current
study was Poly [ADP-ribose] polymerase 1 (PARP-1), which
although normally associated with DNA virus (e.g. (Grady
et al., 2012; Ohsaki et al., 2004; Tempera et al., 2010)) and
retrovirus biology (e.g. (Bueno et al., 2013)) has also been
shown to be a positive factor for inﬂuenza virus biology
(Bortz et al., 2011). To conﬁrm the interaction between
PARP-1 and N protein, independent pulldown assays were
performed. Recombinant protein from an empty negative
control vector (pTriEx1.1 Neo), MBP-His control bait or
recombinant N-His protein were puriﬁed using Nickel-
afﬁnity beads and incubated with a HEK293T cell lysate.
Western blotting was then used to investigate whether
PARP-1 was pulled down by the N protein compared to an
MBP-His control bait (Fig. 3B). The data indicated that
PARP-1 only associated with the N protein in contrast to
the MBP-his control protein or the background matrix.
3.4. Inhibition of PARP-1 disrupts virus biology
To investigate whether PARP-1 was important for virus
biology, the small molecule inhibitor 3-aminobenzamide
(3-AB) was used to treat PRRSV infected cells and virus
biology assayed compared to control infected but untreat-
ed cells. First, several doses of 3-AB (5, 10, 20 and 40 mM)
were assessed against untreated cells in a cell viability
assay to determine the effect of the different doses over the
virological assay period – 96 h. These doses were based on
the reported activity of 3-AB against PARP-1 (Purnell and
Whish, 1980). The data indicated that the doses had some
effect on cell viability compared to the control untreated
cells, ranging from approximately 80% viability after 96 h
of treatment with 40 mM 3-AB to approximately 95%
viability with 5 mM 3-AB (Fig. 4A). In most subsequent
experiments 5, 10 and 20 mM 3-AB was used as this
maintained sufﬁcient levels of cell viability to assay virus
biology over the complete 96 h experimental infection
period.
Different doses of 3-AB were assessed for potential anti-
viral activity by infecting cells with the same MOI of PRRSV
and then treating cells with 5, 10, and 20 mM 3-AB over the
infection period. Progeny virus production was compared
by endpoint dilution assay to an untreated control at 12,
24, 48, 72 and 96 h post-infection. The data indicated that
at the 12, 24 and 48 h time points, using a one-way ANOVA
test, there was no signiﬁcant difference (p > 0.05) in
progeny virus production, however at 72 and 96 h post-
infection there was a signiﬁcant difference (p < 0.05) in
progeny virus production between the treatments com-
pared to the control non-treated infected cells (Fig. 4B).
This was also conﬁrmed using indirect immunoﬂuores-
cence microscopy to detect viral antigens in virus-infected
cells at 24, 48, 72 and 96 h post-infection compared to an
untreated control (Fig. 5A). There were considerably less
foci of infection in the treated cells compared to untreated
control infected cells (Fig. 5B) (data shown for the 20 mM
Fig. 3. (A) Western blot validation of the interaction of two selected
cellular proteins with N protein that were identiﬁed by LC–MS/MS,
hnRNAP A2/B1 and eIF4e, shown are the input cell lysate from 293-T cells,
uninduced and induced his-tag anchored UBC9 protein and his-tagged
anchored N protein. (B) Western blot validation of the interaction of
PARP-1 with the his-tagged PRRSV N protein used as bait. HEK293T cell
lysates were incubated with control baits (his-tagged MBP and beads
bound to bacterial lysates expressing empty pTriEx 1.1 Neo vector which
was used to construct the N protein), or recombinant N protein bound to
nickel beads. Cellular HEK293T lysate inputs are also shown in lane 1 from
left. The cellular lysate inputs and pulldown outputs were detected by
Western blot using antibodies against PARP-1 (upper panel), MBP (middle
panel) or PRRSV N protein (bottom panel), respectively.
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L. Liu et al. / Veterinary Microbiology 176 (2015) 109–119 115centration of 3-AB). This conﬁrmed the titration data
t virus biology was adversely affected by 3-AB, with
s output being reduced to 1–2 log10 at 96 h post-
ction compared to 7 log10 for the infected, but
reated control (Fig. 4B).
There are several stages to a virus life cycle, and the
que assay provided a measure of the amount of virus
ng released into the supernatant. To investigate
ether the PARP-1 inhibitor 3-AB affected virus biology
he cell, the abundance of viral proteins were compared
ng western blot at 24, 48 and 72 h post-infection
ween treated and untreated PRRSV-infected cells
. 6A). The data indicated that at 24, 48 and 72 h
t-infection nsp2, GP2, GP4, GP5, M and N proteins
eared less abundant in 3-AB treated cells than the non-
ted cells (Fig. 6A). Western blot analysis indicated that
in untreated and uninfected cells, PARP-1 was present in
its native state. However, in cells treated with 20 mM 3-AB,
PARP-1 is present as a cleavage product as well as native
protein (Fig. 6B). This is consistent with the cell viability
assay and that PARP-1 is cleaved during apoptosis. PARP-1
is present in the native and cleaved state in infected and
treated cells at 24, 48 and 72 h post-infection. However, in
untreated cells, PARP-1 is present in the native state at 24 h
post-infection and in the native and cleaved state at 48 and
72 h post-infection. This is consistent with cleavage of
PARP-1 previously reported in PRRSV infected cells (Lee
and Kleiboeker, 2007).
As a protein responding to DNA damage or cellular stress,
PARP-1 has been reported to be an enhancer factor for the
optimal function of ﬂu viral polymerase and knockdown of
PARP-1 could result in reduced accumulation of NP in
4. Inhibition of PARP-1 with 3-AB adversely affected the propagation of PRRSV in Marc-145. (A) Cell viability assay of Marc-145 cells cultured at various
entrations of 3-AB. Marc-145 cells were treated with the indicated concentrations of 3-AB and toxicity determined by measuring succinate
ydrogenase level at intervals of 24 h. One-way ANOVA test showed that 3-AB treated cells were less viable compared with control (p < 0.05). (B)
viral activity of PARP-1 in Marc-145. Cells were infected with PRRSV at MOI of 1 and maintained in the presence of indicated concentrations of 3-AB.
eny viruses were harvested at intervals of 24 h and viral production was determined by endpoint dilution. One-way ANOVA test was done to compare
 treated virus output with untreated control. The treatments resulted in signiﬁcant differences were indicated with * (p < 0.05).
L. Liu et al. / Veterinary Microbiology 176 (2015) 109–119116H5N1-infected A549 cells (Bortz et al., 2011). To investigate
whether PARP-1 is involved in the replication and tran-
scription of viral RNAs, viral genomic RNA (detected using
primers in ORF1 encoding for Nsp1) and subgenomic RNAs
(detected using primers in the gene encoding for N) in PRRSV
infected cells were quantiﬁed by real time RT-PCR, and
compared with the viral RNAs produced in PARP-1 inhibitor
3-AB treated cells. The result showed that inhibition the
function of PARP-1 signiﬁcantly reduced the production of
PRRSV genomic (P < 0.01) and subgenomic RNAs (P < 0.05)
(Fig. 6C), suggesting that PARP-1 acted as a positive factor for
PRRSV infection.
3.5. 3-AB exhibits resistance-free antiviral activity against
PRRSV
Viruses with RNA genomes can rapidly render antiviral
compounds ineffective through acquisition of drug resis-
tance by high mutation rates and this remains a major
challenge in antiviral therapy. To investigate whether
inhibiting PARP-1 with 3-AB maintained antiviral activity
with sequential passage we adopted a similar approach to
that used for screening HSP90 inhibitors against human
respiratory syncytial virus (Geller et al., 2013). PRRSV was
sequentially passaged 15 times in the presence of four
different concentrations of 3-AB; 5, 10, 20 and 40 mM.
Virus was taken at the end of passage 15 and its growth
compared to the growth of virus that had not been
passaged in the inhibitor and was exposed to the inhibitor
for the ﬁrst time. The passage 15 virus was equally as
sensitive to 3-AB as the control virus (Fig. 7), indicating
that prolonged treatment with the 3-AB PARP-1 inhibitor
did not select for drug resistant viral mutants.
4. Discussion
RNA viruses such as PRRSV represent a major threat to
global health and food security. Conventionally viral
proteins have been targeted as part of anti-viral therapy,
but due to the error prone nature of replication, resistant
strains can rapidly emerge. Targeting cellular proteins that
are critical for virus function may provide a therapeutic
Fig. 5. Immuno-ﬂuorescence analysis of PRRSV infected Marc-145 with and without PARP inhibitor. Cells were incubated for indicated hours after infection
and treatment with 20 mM 3-AB or DMSO as control. PRRSV infections were detected by IFA with swine anti-PRRSV serum and FlTC-conjugated rabbit anti-
pig IgG antibody. (A) The immuno-ﬂuorescence images were taken at an excitation wavelength of 495 nm with ﬂuorescence microscope equipped with an
appropriate ﬁlter. (B) Infection rate of Marc-145 determined by IFA. The percentage of infected cells were calculated by dividing the number of ﬂuorescent
cells by the total cells in the corresponding ﬁeld. Each datum was obtained as the mean value from triplicate images.
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 therapies. Many cellular processes can be targeted
siently without long-term ill effects, and therefore
h anti-cellular viral therapy may lend itself to acute
er than persistent infections. Targeting selected
ular proteins may provide broad-spectrum anti-viral
ivity. For example, inhibiting the function of protein
perones (e.g. heat shock proteins) has been demon-
ted for a wide range of viruses including infection of
s with inﬂuenza virus (Chase et al., 2008), HRSV (Geller
al., 2013; Radhakrishnan et al., 2010; Munday et al.,
4), rabies virus (Lahaye et al., 2012) and Ebola virus
ith et al., 2010; Garcia-Dorival et al., 2014).
To identify cellular proteins that could be targeted as
part of anti-viral strategies proteomics can be used. This
can be at a global level to identify host cell metabolic
processes (Dove et al., 2012; Emmott et al., 2010; Munday
et al., 2010) or speciﬁcally identifying cellular proteins that
interact with viral proteins (Emmott et al., 2013; Jourdan
et al., 2012a; Wu et al., 2012). This study adopted the latter
approach and used proteomics to determine the cellular
interactome of PRRSV N protein. This interactome was
elucidated under conditions that did not promote cellular
stress pathways and involved the puriﬁcation of a
recombinant N protein as bait and pulldown assays used
to identify cellular interacting partners from a cell lystate.
Using a conservative selection criteria, 108 proteins were
identiﬁed that could potentially interact with the N
protein, or be part of larger complexes, which associated
with the N protein. The selection criteria were based on
cellular proteins being identiﬁed by two or more peptides
and having a binding ratio higher than two fold compared
to the control bait protein.
Analysis of the list identiﬁed PARP-1 as a cellular
protein that could interact with the N protein and which
also had a small molecule, 3-AB, that inhibited its function
(Purnell and Whish, 1980). The inhibitor has been used
both in vitro and in vivo. In the present study, the use of 3-
AB demonstrated that PARP-1 activity was required for
PRRSV biology, and therefore PARP-1 could be considered
as positive viral factor. Our data have shown that PRRSV N
protein interacts with PARP-1 and inhibition of PARP-1
signiﬁcantly reduces the production of the viral genomic
and subgenomic RNAs, indicating that PARP-1 may be
recruited by N protein and beneﬁt for the viral RNA
replication and transcription processes. This result is
7. 3-AB sensitivity assay based on an assay used to assess the effect of
90 inhibitors against HRSV (Geller et al., 2013). PRRSV was
entially grown for 15 passages in various concentrations of 3-AB.
c-145 cells were infected with PRRSV from the ﬁnal passage or from
original stock for 72 h in the presence of indicated concentrations of 3-
Viruses released into the supernatant were titrated by endpoint
tion. Each datum represents the mean TCID50/0.1 ml of 2
riments.
6. Validation of the antiviral effect of PARP-1 inhibitor in Marc-145. Cells were inoculated with 1 MOI of PRRSV and treated with 20 mM or without 3-AB.
r incubation for the indicated time, cells were lysed and analyzed by Western blotting with swine anti-PRRSV antibody (A), and rabbit anti-PARP-1
body (B). Protein bands on the western blot were labeled according to previous reported studies (Li et al., 2012; Music and Gagnon, 2010). b-Actin was
 detected by anti-b-actin antibody to normalize the protein amount of cell lysates loaded in lanes (lower panel in A & B). (C) Quantization of PRRSV
mic (Nsp1) and subgenomic (N) RNA in infected Marc-145 cells. Total RNA was extracted at 24hpi and subjected to real-time RT-PCR analysis. Relative
ls of N and Nsp1 were calculated using GAPDH as an internal control. Data were shown as means SD of three independent experiments. One-way
VA test was done to compare N and Nsp1 RNA level in 3-AB treated cells with untreated control (*P < 0.05; **P < 0.01).
L. Liu et al. / Veterinary Microbiology 176 (2015) 109–119118consistent with the report that PARP-1 is a positive factor
for the optimal function of viral polymerases in inﬂuenza
infection, although the precise mechanisms remain to be
resolved.
Prolonged treatment of PRRSV infected cells with 3-AB
did not select for drug resistant viral mutants, at least over
15 passages. Here we used a similar strategy that was used
to investigate an inhibitor of a cellular protein important
for HRSV (Geller et al., 2013). Whilst we could have
increased the concentration of 3-AB from 20 mM to 40 mM
for the selection/reversion experiment, this latter concen-
tration may have reduced the number of viral genomes by
too much to generate sufﬁcient numbers for selection
experiments. Although it is hard to predict how many
passages or viral generation times should be tested, it is
worth noting that two amino acid substitutions in the N
protein that abolish its nuclear localization (NLS) (Pei et al.,
2008), underwent strong selection pressure both in vitro
and in vivo that resulted in partial or complete reversion
and gain of NLS activity (Pei et al., 2008).
Taken together our data suggests that that PARP-1 is
important for the virus life cycle and cannot be substituted
by the function of another cellular protein. In a wider
context determining the cellular interactome of viral
proteins can be used to identify cellular proteins whose
functions can be ablated with small molecule inhibitors to
disrupt virus biology. This adds to the general principle
that is being established in anti-viral therapy (Baillie and
Digard, 2013) that targeting cellular proteins may provide
an attractive alternative and expand the repertoire of anti-
viral inhibitors (Xiao et al., 2014; Munday et al., 2014;
Garcia-Dorival et al., 2014).
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